




NAFLDsym®




NAFLDsym® is Quantitative Systems Pharmacology (QSP) software capable of Exploring and Predicting Efficacy for Novel Fatty Liver Disease Treatments

Sound Science

- DILIsym Services, Inc. has leveraged its long standing expertise in liver physiology and metabolic diseases to develop NAFLDsym®, which is used to evaluate the potential of new drug candidates to treat non-alcoholic fatty liver disease (NAFLD)
- NAFLD is a prevalent, worldwide disease with few available treatment options
- Successful application examples already completed for active drug candidates (publications in preparation)

Capable - Key Components Include:

- Steatosis
- Regulation of liver triglyceride and fatty acids
- Lipotoxicity
- >300 simulated patients with variability in NAFLD pathophysiology
- Liver regeneration / proliferation
- Hepatocellular bioenergetics
- Innate immune system and inflammatory mediators
- Dynamic body weight and its effects on lipids
- Biomarkers (e.g., ALT, AST, cytokeratin cleaved K18)
- Fibrosis and inflammation sub-models in development
- Integrated with DILIsym® to enable parallel prediction of hepatotoxic potential



Application Driven

- Evaluate targets and/or specific compounds utilizing key laboratory and/or clinical data describing DMPK and pharmacodynamic characteristics
- Prioritize compounds and targets
- Optimize clinical trial protocols by determining favorable dosing paradigms and outcome (i.e., liver fat reduction) measurement frequency